细胞外囊衍生的非编码RNA对前转移性和瘤进展的影响
Zhuang Chen1,2, Qiming Wang3, Jinbo Liu1
1Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.
Genes & diseases
|August 17, 2023
概括
细胞外囊泡衍生的非编码RNAs (EV-ncRNAs) 通过改变免疫抑制,血管化和新陈代谢来创建前转移性 (PMNs). 这些EV-ncRNA显示出作为癌症生物标志物和治疗点的前景.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 细胞生物学 细胞生物学
背景情况:
- 转移前位 (PMN) 是关键的微环境,支持远处器官的瘤细胞殖民.
- 细胞外囊泡 (EVs) 通过载荷转移进行细胞间通信,包括非编码RNA (ncRNAs).
- EV衍生的ncRNAs (EV-ncRNAs) 在PMN形成中的作用是一个快速增长的研究领域.
研究的目的:
- 审查EV-ncRNAs对转移前利基的多方面的影响.
- 为各种癌症类型提供EV-ncRNA功能的全面概述.
- 讨论EV-ncRNAs作为诊断,预后和治疗剂的临床潜力.
主要方法:
- 文献综述综合了关于EV-ncRNA和PMN的当前研究.
- 对PMN特征的EV-ncRNA影响的分类:免疫抑制,血管透性,血管生成,炎症,代谢重编程和纤维细胞激活.
- 在不同癌症背景下分析EV-ncRNA的作用.
主要成果:
- EV-ncRNAs通过调节免疫抑制和血管生成等关键过程,显著影响PMN的发展.
- 具体的EV-ncRNA在促进或抑制PMN形成方面具有不同的作用,具体取决于癌症类型.
- EV-ncRNAs参与改变瘤微环境,包括炎症和代谢转变.
结论:
- EV-ncRNAs是前转移性的建立和功能中的关键调解者.
- 了解EV-ncRNA机制为癌症转移提供了洞察力.
- EV-ncRNAs代表了癌症诊断和预后的有希望的生物标志物,以及新型治疗的潜在目标.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.9K
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
10.3K
相关概念视频
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
